Last checked at 10 Jun 2013 07:00
Oxford BioMedica plc
Director's Share Purchase
Oxford, UK - 10 June 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, was informed on 7 June 2013 that six of its Directors had acquired ordinary shares of 1p each ("Ordinary Shares") as follows:
|
|
|
| Interest after purchase | |
Director / PDMR | Title | Price per share (p) | Number of Ordinary Shares acquired on 07 June 2013 | Number of Ordinary Shares | % of total issued share capital |
Paul Blake | NED | 1.750 | 113,097 | 533,097 | 0.037% |
John Dawson | CEO | 1.750 | 282,829 | 2,282,829 | 0.161% |
Andrew Heath | NED | 1.789 | 180,000 | 500,000 | 0.035% |
Peter Nolan | SVP | 1.750 | 169,675 | 733,313 | 0.052% |
Nick Rodgers | Chairman | 1.750 | 282,829 | 634,829 | 0.045% |
Timothy Watts | CFO | 1.750 | 282,829 | 3,282,829 | 0.232% |
The issued share capital of the Company is 1,416,149,005 1p ordinary shares.
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications | Tel: +44 (0)1865 783 000 |
Nomura Code Securities Limited: Juliet Thompson/Jonathan Senior/Christopher Golden | Tel: +44 (0)20 7776 1200 |
Media Enquiries: Mary-Jane Elliott/Sarah Macleod/Claire Dickinson M:Communications |
Tel: +44 (0)20 7920 2360 |
Notes to editors
1. About Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.